In the current study, we performed an extensive immunohistochemical and molecular analysis of biological markers related with the PI3K/Akt/mTOR and Ras/MAPK signalling pathways in a series of HER2-positive BC patients who received trastuzumab for metastatic disease or as first-line therapy in earlier stages. This evidence concerns the gene MTOR and metastatic neoplasm.